United Therapeutics Corporation (UTHR) Shares Bought by CIBC World Markets Inc.

CIBC World Markets Inc. grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 223.9% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 20,898 shares of the biotechnology company’s stock after buying an additional 14,447 shares during the period. CIBC World Markets Inc.’s holdings in United Therapeutics Corporation were worth $2,711,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. BlackRock Inc. increased its holdings in shares of United Therapeutics Corporation by 4,222.8% during the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock worth $641,969,000 after buying an additional 4,632,287 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of United Therapeutics Corporation by 308.6% during the second quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock worth $64,930,000 after buying an additional 378,002 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of United Therapeutics Corporation by 27.8% during the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock worth $235,068,000 after buying an additional 377,395 shares in the last quarter. Schroder Investment Management Group increased its holdings in shares of United Therapeutics Corporation by 42.8% during the second quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock worth $143,359,000 after buying an additional 327,360 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of United Therapeutics Corporation by 7.3% during the first quarter. Vanguard Group Inc. now owns 3,785,099 shares of the biotechnology company’s stock worth $512,427,000 after buying an additional 256,514 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This story was first published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/09/12/united-therapeutics-corporation-uthr-shares-bought-by-cibc-world-markets-inc.html.

Several analysts have recently weighed in on the stock. BidaskClub lowered shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Jefferies Group LLC reissued a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research note on Friday, July 14th. Six research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the stock. United Therapeutics Corporation has a consensus rating of “Hold” and a consensus target price of $134.50.

United Therapeutics Corporation (NASDAQ UTHR) opened at 120.75 on Tuesday. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89. The stock’s 50 day moving average is $130.11 and its 200-day moving average is $130.35. The company has a market capitalization of $5.25 billion, a PE ratio of 14.00 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The firm had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. During the same period in the prior year, the company posted $4.42 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, analysts expect that United Therapeutics Corporation will post $10.09 EPS for the current year.

In other news, Director Raymond Dwek sold 3,490 shares of the company’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $131.71, for a total value of $459,667.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 1,232 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $133.32, for a total transaction of $164,250.24. Following the completion of the sale, the chief executive officer now directly owns 2,301 shares in the company, valued at $306,769.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,178 shares of company stock worth $3,289,427. Insiders own 7.80% of the company’s stock.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply